Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018
Open Access
- 23 May 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Blood Cancer Journal
- Vol. 8 (5), 1-8
- https://doi.org/10.1038/s41408-018-0080-9
Abstract
Immunoglobulin light chain amyloidosis (AL) should be considered in any patient that presents to a cancer care provider with nephrotic range proteinuria, heart failure with preserved ejection fraction, non-diabetic peripheral neuropathy, unexplained hepatomegaly or diarrhea. More importantly, patients being monitored for smoldering multiple myeloma and a monoclonal gammopathy of undetermined significance (MGUS) are at risk for developing AL amyloidosis. MGUS and myeloma patients that have atypical features, including unexplained weight loss; lower extremity edema, early satiety, and dyspnea on exertion should be considered at risk for light chain amyloidosis. Overlooking the diagnosis of light chain amyloidosis leading to therapy delay is common, and it represents an error of diagnostic consideration. Algorithms will be provided on how to evaluate patients with suspected AL amyloid as well as how to manage patients referred from other medical specialties with biopsy-proven amyloid. An organized stepwise approach to the treatment of patients with light chain amyloidosis, including established and investigational therapies, will be reviewed.Keywords
This publication has 97 references indexed in Scilit:
- Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trialBMC Medicine, 2014
- Paraneoplastic neuropathiesCurrent Opinion in Neurology, 2013
- Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosisBlood, 2012
- Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosisBlood, 2012
- Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosisBlood, 2011
- Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse modelsJournal of Translational Medicine, 2010
- Discordance between serum cardiac biomarker and immunoglobulin‐free light‐chain response in patients with immunoglobulin light‐chain amyloidosis treated with immune modulatory drugsAmerican Journal of Hematology, 2010
- The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosisBlood, 2006
- Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice modelThe FASEB Journal, 2006
- Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantationBlood, 2004